About Us
ACADIA Pharmaceuticals is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. More »
News
May 15, 2012
ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
May 08, 2012
ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results
Product Candidates
Our clinical pipeline consists of four product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. More »
Company Information
 |
Request Information » |
 |
Investor Webcasts » |  |
Email Updates » |